Richard Carvajal on Immunotherapy Dosing
Richard Carvajal, MD, discusses how to make decisions regarding the dosing limits of immunotherapy agents.
Richard Carvajal, MD, from Columbia University Medical Center discusses deciding on dosing limits for immunotherapy treatments.
The proper dosing for immunotherapy efficacy is unclear. For chemotherapy, the patients can often be pushed to toxicity. However, with immunotherapies and targeted therapies, there are responses seen after 1 or 2 doses. There are also durable responses in some patients if treatment is stopped.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
September 11th 2024This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
